Thursday 14 November 2024

The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?

Pharmaceutical
Simon Wentworth
10 February 2022
the-pharma-letter-podcast-episode-10

More on this story...

Biotechnology
The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery
30 December 2021
Biotechnology
The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?
14 December 2021
Biotechnology
The Pharma Letter Podcast — Episode 11 — Should US states control drug prices?
4 March 2022
Biotechnology
The Pharma Letter Podcast — Episode 13 — Is there a data capture crisis in biotech?
5 April 2022


More ones to watch >


Today's issue

Former Mirati CMO Alan Sandler joins ALX Oncology
Biotechnology
Former Mirati CMO Alan Sandler joins ALX Oncology
14 November 2024
Biotechnology
Merck & Co wades into PD-1/VEGF space via deal with LaNova Medicines
14 November 2024
Pharmaceutical
Positive results for Microbion’s new diabetic foot ulcer drug
14 November 2024
Pharmaceutical
ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline
14 November 2024
Pharmaceutical
Momentum flagging, a Phase III data win spurs tirzepatide
14 November 2024
Pharmaceutical
Merck KGaA shares slip on cautious outlook
14 November 2024
Biotechnology
AC Immune Phase II ACI-7104.056 success in Parkinson’s
14 November 2024

Company Spotlight

A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.




More Features in Pharmaceutical

Positive results for Microbion’s new diabetic foot ulcer drug
14 November 2024
ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline
14 November 2024
Momentum flagging, a Phase III data win spurs tirzepatide
14 November 2024
Merck KGaA shares slip on cautious outlook
14 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze